Chemoprevention with a Long Acting Somatostatin Analogue in a Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mouse Model Does Delay the Progression of Pancreatic Neuroendocrine Neoplasms (pNENs)

#1488

Introduction: Long acting somatostatin analogues (LAR) are an essential part of the treatment of neuroendocrine tumours.

Aim(s): The aim of this study was to evaluated the chemopreventive effects of a long acting somatostatin analogue on the development of pancreatic neuroendocrine neoplasms (pNENs) in a MEN1 Knockout mouse model.

Materials and methods: MEN1 knockout mice were treated with monthly subcutaneous injections of the somatostatin analogue Lanreotid (Somatuline Autogel ©;Ipsen Pharma) or a placebo, starting at day 35. Mice were killed after a determined period (after 6, 9, 12, 15 and 18 months, each group contained 5 mice) and size of pNENs were measured due histological analysis and compared to the control group.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lopez C

Authors: Lopez C, Bartsch D, Albers M, Bollmann C, Roth S,

Keywords: chemoprevention, neuroendocrine neoplasms, somatostatin analogue ,